Opyt primeneniya azilsartana medoksomila (Edarbi) u patsientov s arterial'noy gipertenziey v ambulatornoy praktike

The article presents the results of the clinical evaluation of the the efficacy and tolerability of monotherapy with azilsartan medoxomil in 120 patients with I-II degree arterial hypertension. It was shown that azilsartan medoxomil used as monotherapy for 3 months at doses of 40 and 80 mg is an effective antihypertensive agent. It significantly improves the stiffness of the elastic and mixed type arteries, which helps to reduce the rigidity of the vascular wall, prevents vascular remodeling and development of atherosclerotic lesions. The drug was well tolerated by patients. There was a statistically significant decrease in blood glucose levels during treatment with azilsartan medoxomil. It is shown that azilsartan has nephroprotective properties, and significantly reduces the microalbuminuria. As a result, the drug significantly improves the quality of life of patients and reduces the level of anxiety according the Hamilton scale score.

arterial hypertension, antihypertensive therapy, angiotensin receptor blockers, azilsartan medoxomil